Nektar soars–again–on oncology drug data
Shares of Nektar Therapeutics (NKTR) are up another 16% this morning to $37.89 as of noon New York time on data presented this weekend at the annual meeting of the Society for Immunotherapy of Cancer from an early trial of Nektar's NKTR-214. The data looked at the...
Nektar rockets ahead, options in my Volatility Portfolio head for orbit
On the evening of October 31 I wrote that a decision onwhat to do with the Netkar Therapeutics options (NKTR180119C00022000)--the January 19, 2018 call at $22--that I added to my Volatility Portfolio back on May 16, 2017 at a price of $2.64 (the closing options price...
Rebalancing portfolios In January 2018 looks like a smart response to the momentum and concentration of winners in 2017
You don’t have to do anything now–but come January 2018, if 2017 finishes the way I outlined in my last post on this momentum market and end of the year selling/window dressing I think rebalancing a portfolio will be a very smart way to begin 2018. Rebalancing–selling winning positions and adding to losing positions until all the holdings in a portfolio are equally weighted–will automatically take profits in the biggest winners of 2017 and redistribute some of that cash into stocks that have been sold down in 2017 but that look set to rebound in 2018.
My last post setting up my new Perfect 5 ETF Portfolio: How to use it along with my Volatility Portfolio
I’ve named the five ETFs in this portfolio. Explained my ideas on allocation money among those five ETFs and their associated asset classes. And discussed the importance of knowing what index an ETF follows. Now it’s time to explain one last thing to complete the set up of this new portfolio: Why I’ve positioned it next to my Volatility Portfolio on JugglingWithKnives.com and JubakAM.com.
Brazil’s president dodges trial again–who says vote-buying doesn’t work?
Brazil’s President Michel Temer has once again escaped a trial for corruption after an effort to send charges against Temer to the Supreme Court failed to get the necessary 2/3 majority in Congress required before a sitting president can be forced to stand trial.
Brazil’s stock market sees light at the end of the tunnel–I agree and am adding ETF EWZS to my Volatility Portfolio today
The political turmoil is by no means over and with embattled President Michel Temer facing another vote in Congress over whether he will stand trial for corruption, there's likely to be at least one more round of fiscally irresponsible vote-buying outlays by the...
Why a portfolio of “passive” ETFs requires active management by you–announcing my new ETF portfolio to do just that
Can I clear up one bit of confusion? ETFs are indeed passively managed investment vehicles. Their portfolios passively follow indexes rather than allocating money into the picks of a fund manager. But portfolios of ETFs put together by investors aren’t–and indeed can’t be–passively managed. And that’s why, this week, I’m launching my new Perfect 5 Active Passive ETF portfolio.
Sell my emerging markets short ETF on China credit downgrade today
This probably seems counter-intuitive but I'm selling my emerging markets short, the Proshares Short MSCI Emerging Markets ETF (EUM), out of my Volatility and Jubak Picks portfolios on Standard & Poor's one notch downgrade of China's sovereign credit rating to A+...
Adding MGM March 16 2018 calls at $33 to my Volatility Portfolio
This is another news event trade--with more time allowed before the event and for the event to play out. This trade is an effort to add leverage on that news to my equity position in MGM Resorts International (MGM) in my Jubak Picks Portfolio. Before the end of the...
Lessons from my bad trade in INCY call options in my Volatility Portfolio
Wow. That sure didn’t work the way I intended. Back on May 23 I added the July 21 $140 calls on Incyte (INCY) to my Volatility Portfolio. Those calls traded at $7.10 that day. As I wrote in my post that day, to make money on these options, I’d need to get a move of $4 or so to move the share price above $140 and to move the options into the money. My logic at the time was pretty simple.
Nervous market has been hard on Nektar; hold options in my Volatility Portfolio for September news (and beyond)
Biotechs--and indeed any high price-to-earnings stocks perceived as risky--have taken more than their share of punishment in the nervous sell off of the last few weeks. Nektar Therapeutics (NKTR), for example, closed yesterday August 21 at $17.79. That's down from...Jim’s Stock Alerts
Download Jim’s eBook for Free
